ArticleScientific reports2026
The aMAP score combined with plasma cfDNA methylation testing for risk stratification in hepatitis population: a case-control study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Effective surveillance of the hepatitis populations reduces liver cancer incidence and improves prognosis. This study aimed to develop an easy and non-invasive risk assessment model for this population. A total of 392 subjects were included in the present study, comprising 72 cases of chronic hepatitis, 31 cases of liver fibrosis, 152 cases of cirrhosis and 137 cases of liver cancer from diverse ethnic groups in China. Concurrent evaluation of the methylation levels of the GNB4 and Riplet genes in plasma, alongside the age-male-albumin-bilirubin-platelet (aMAP) score and serum AFP, was performed for each subject. Head-to-head comparisons demonstrated that methylation is a superior diagnostic biomarker for liver cancer relative to AFP and aMAP scores. The sensitivity and specificity of GNB4/Riplet methylation for detecting liver cancer were 87.59% (95% confidence interval [CI]: 80.61%-92.40%) and 93.33% (95% CI: 89.25%-95.95%), respectively. For TNM stage I and II liver cancer, methylation showed sensitivities of 69.70% (95% CI: 51.13%-83.79%) and 91.18% (95% CI: 75.19%-97.69%), respectively. The aMAP score yielded an area under the curve (AUC) of 0.745 (95% CI: 0.679–0.812) for differentiating hepatitis from fibrosis/cirrhosis/cancer samples, and an AUC of 0.764 (95% CI: 0.710–0.818) for differentiating hepatitis/fibrosis from cirrhosis/cancer samples. When combining the aMAP score with methylation, the corresponding AUCs increased to 0.825 (95% CI: 0.774–0.875) and 0.867 (95% CI: 0.829–0.905), respectively. The combination of aMAP score and plasma GNB4/Riplet gene methylation shows promise as a tool for risk stratification, which needs external validation in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.